Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Defense was posted on June 25, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

DoW Neurofibromatosis Synergistic Idea Award

Closed
HT942526NFRPSIAGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 15 hours ago

DEADLINE

in 11 months
NAICS: 541715
New
Grant
Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-002
Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.
National Institutes Of Health

POSTED

about 23 hours ago

DEADLINE

in 5 months
NAICS: 541715
New
Grant
National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-001
Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.
National Institutes Of Health

POSTED

about 23 hours ago

DEADLINE

in about 1 year

AI Contract Overview

Show more

The Defense Health Agency is soliciting applications for the fiscal year 2026 Neurofibromatosis Research Program Synergistic Idea Award (SIA) under solicitation number HT942526NFRPSIA. This program supports new, synergistic research approaches to neurofibromatosis involving two or three Principal Investigators who utilize complementary perspectives to address central problems in NF research. The initiative seeks a wide range of disciplines, including basic science, engineering, bioinformatics, population science, translational research, and clinical research. Funding is allocated to support two awards with a cost cap of 3.2 million dollars per award over a maximum period of performance of three years. The application process requires a pre-application phase with a Letter of Intent due September 8, 2026, followed by full applications due September 22, 2026. An Initiating PI manages administrative tasks, while Partnering PIs submit separate applications; all PIs must provide an identical Statement of Work. Evaluation follows a two-tier process focusing on technical merit and programmatic relevance, with pass/fail gates for SAM registration and foreign affiliation disclosures. Awardees must adhere to Department of Defense Grant and Agreement Regulations and provide annual and final technical progress reports. Research involving human or animal subjects requires approval from the DHA R&D ORRC and local ethics committees.

General Info

DHA seeks synergistic neurofibromatosis research applications; two awards up to 3.2 million dollars.

Documents

1

FY26 Neurofibromatosis Research Program Synergistic Idea Award HT942526NFRPSIA

PDF, High priority: read this firstrfp
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
Contacts1 person available
OfficeUSA

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Synergistic Idea Award (SIA) supports new ideas that represent synergistic approaches to neurofibromatosis (NF) research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.


Distinctive Features:

• Partnering Principal Investigators: One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. An additional one or two PI(s) will be identified as a Partnering PI. Each partner will be recognized as a PI, submit a separate application (even if the partners are at the same organization), and receive an individual award.

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Defense Health Agency Contracting Activity is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation HT942526BCRPBTA122. This program aims to fund high-impact research capable of producing breakthroughs in breast cancer treatment and understanding. Funding Level 1 supports early-stage, high-risk, high-reward research focused on proof of concept without requiring preliminary data, while Funding Level 2 supports research validated by substantial preliminary or published data to facilitate clinical translation. A specialized Population Science Studies option is available under Level 2. The program expects to allot approximately 10.6 million dollars to fund roughly six applications. Eligible applicants may apply as a single Principal Investigator or through a Partnering PI Option. Funding limits vary by level and PI structure, ranging from 750,000 dollars for a single PI at Level 1 up to 3.35 million dollars for partnering PIs conducting Population Science Studies at Level 2. The maximum period of performance is three years, extending to four years for Population Science Studies. Applications are evaluated based on impact, research strategy, and feasibility, with personnel and partnership qualifications also considered. The application process is a two-step submission requiring a pre-application by November 4, 2026, and a full application by November 18, 2026. Required documentation includes a project narrative, statement of work, and various abstracts and statements submitted as specific PDF attachments. Applicant organizations must maintain active registration in SAM.gov and provide a Unique Entity Identifier. Additionally, all key personnel must disclose foreign affiliations, and clinical research proposals must include a Public Health Service Inclusion Enrollment Report.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details
NAICS: 541715
Grant
DoW Breast Cancer, Clinical Research Extension Award
Solicitation # HT942526BCRPCREA2
The FY26 Breast Cancer Research Program Clinical Research Extension Award, solicitation HT942526BCRPCREA2, is a grant opportunity issued by the Defense Health Agency Contracting Activity to support research that extends data collection, follow-up, and analysis of breast cancer clinical studies. The program aims to recover knowledge lost due to early trial termination, limited patient follow-up, or suboptimal data collection, including projects involving deeper molecular analysis of clinical samples. All applications must address at least one FY26 BCRP overarching challenge. The research team is required to include at least two breast cancer consumer advocates. Funding allows for a single Principal Investigator or a partnering arrangement between an Initiating PI and a Partnering PI. The application process is a two-step submission requiring a pre-application Letter of Intent by November 4, 2026, and a full application by November 18, 2026. Pre-applications are submitted via eBRAP, while full applications are submitted through eBRAP for intramural DOW organizations and Grants.gov for extramural organizations. Awards have a maximum period of performance of four years. Evaluation follows a two-tier system consisting of a peer review for technical merit and a programmatic review for relevance. Scored criteria include impact, research strategy and feasibility, partnership (for PPIO applications), and the research sharing plan. Applicants must be registered in SAM.gov with an active status and a Unique Entity Identifier.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS